Company intelligence / Profile preview

Canadian Nuclear Laboratories

Chalk River, Ontario, Canada

Ownership: Private
Employees: ~3200
Development stage: Other

Overview

CNL is a leader in radiopharmaceutical research and medical isotope production, notably actinium-225 for clinical and preclinical cancer trials; research efforts have led to international standards for dose measurement and foundational advances in targeted alpha therapies

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalTargeted alpha therapyRadioisotopeAntibody
Industry: Academic Hospital/University/Research

Partnerships

Canadian National Energy AllianceCollaborations with Canadian and international universities/research institutesSMR vendorsFederal funding and broad governmental collaborations

Beyond the preview

Go deeper on Canadian Nuclear Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Canadian Nuclear Laboratories.

Explore the full profile